drugset / Trial / NCT02276248

Radiotherapy Combined With GDP Chemotherapy in Stage I/II Extranodal Natural Killer/T-cell Lymphoma

NCT02276248 ↗

Phase 2 Completed 40 enrolled Chinese Academy of Medical Sciences
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the efficacy and safety of radiotherapy combined with GDP (gemcitabine, cisplatin, dexamethasone) chemotherapy in stage I/II extranodal natural killer/T-cell lymphoma patients with unfavorable prognostic factors.

Timeline

Start
2010-06
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Cisplatin Other / unclassified 25 mg/m2 Intravenous
Subject Dexamethasone Small molecule 20 mg Oral
Subject Gemcitabine Small molecule 1000 mg/m2 Intravenous